REBEL EM is licensed under a
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
- All Categories
- Abdominal and Gastrointestinal
- Allergy and Immunology
- Cardiovascular
- Dermatology
- EMS and Disaster
- Endocrine, Metabolic, Fluid, and Electrolytes
- Environmental
- Ethical and Legal
- Head, Eye, Ear, Nose, and Throat
- Hematology and Oncology
- Human Behavior
- Infectious Disease
- Neurology
- Obstetrics and Gynecology
- Orthopedics
- Pediatrics
- Procedures and Skills
- Psychiatry/Behavioral Health
- Renal and Genitourinary
- Resuscitation
- Team Performance
- Thoracic and Respiratory
- Toxicology
- Trauma
- All Categories
- Abdominal and Gastrointestinal
- Allergy and Immunology
- Cardiovascular
- Dermatology
- EMS and Disaster
- Endocrine, Metabolic, Fluid, and Electrolytes
- Environmental
- Ethical and Legal
- Head, Eye, Ear, Nose, and Throat
- Hematology and Oncology
- Human Behavior
- Infectious Disease
- Neurology
- Obstetrics and Gynecology
- Orthopedics
- Pediatrics
- Procedures and Skills
- Psychiatry/Behavioral Health
- Renal and Genitourinary
- Resuscitation
- Team Performance
- Thoracic and Respiratory
- Toxicology
- Trauma
Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?
Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli ...
The ACTION Trial: DOACs in Hospitalized Patients with COVID-19
Background: Patients hospitalized with COVID-19 are at increased risk for both arterial and venous thromboembolic disease. Multiple recent trials have investigated the efficacy of therapeutic or standard prophylactic anticoagulation in preventing thrombotic complications among patients with COVID-19 in a variety ...
REBEL Core Cast 75.0 – Femoral Lines
Take Home Points: Newer data suggests that the infection and DVT rates for femoral lines are similar to that for internal jugular central lines. In a resuscitation situation, there are likely faster ways to obtain access than a femoral line ...
Management of Digoxin Toxicity
A 78-year-old woman is brought in by EMS after her husband called 911 for increased confusion associated with intractable vomiting. On arrival to the emergency department (ED), the patient is altered with a heart rate of 48 and a blood ...
REBEL Cast Ep107: The BOUGIE Trial – Bougie First in All Emergency Intubations?
Background: Emergency endotracheal intubation is a potentially life-saving procedure in the management of critically-ill patients. The inherent risks associated with the procedure challenge us to refine our skills and adopt new techniques that can improve our performance. The bougie is ...
The MICHELLE Trial: Anticoagulation Post-Discharge in Patients Hospitalized Secondary to COVID-19
Background: Patients diagnosed with COVID-19 have an increased risk of thromboembolic events, including pulmonary embolism and deep vein thrombosis (DVT). In addition, COVID-19 patients with increased coagulation parameters such as D-dimer, fibrin degradation products, prothrombin time, and activated partial thromboplastin ...
REBEL Core Cast 74.0 – Cauda Equina Syndrome
Take Home Points: Cauda equina syndrome is a rare emergency with devastating consequences Early recognition is paramount as the presence of bladder dysfunction portends bad functional outcomes The presence of bilateral lower extremity weakness or sensory changes should alert clinicians ...
REBEL Crit Cast Ep6.0 – Mastering Mechanical Ventilation Part 1
Mechanical Ventilation is a modality commonly used in the critically ill, but many providers, may not have a strong understanding of the basics. Emergency Medicine and Critical Care Physicians need to have a firm grasp of the basic concepts of ...
The MOVe-Out Trial: Molnupiravir – Oral Antivirals for Management of Covid-19?
Background: On December 23, 2021, the FDA granted molnupiravir emergency use authorization for the treatment of patients with Covid-19. Molnupiravir is a nucleoside analog that inhibits SARS-CoV-2 replication and triggers viral RNA mutagenesis. Until the release of oral antivirals, clinicians ...
Showing Slide 1 of 11
Get new posts (free)
1 email per week. No spam.
Trending Posts
Sponsored